Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neoplasm Metastasis 2Leukemia 2Pancreatic Neoplasms 1Neoplasm, Residual 1Melanoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 23blinatumomab 18Cytarabine 16fludarabine 13Azacitidine 12venetoclax 10fludarabine phosphate 10Rituximab 8Blood Specimen Collection 8Methotrexate 7Lenalidomide 7Dexamethasone 7Daunorubicin 7Mercaptopurine 6Vincristine 5daratumumab 4Whole-Body Irradiation 4Melphalan 4Idarubicin 4Etoposide 4Drug Therapy 4Busulfan 4pembrolizumab 3obinutuzumab 3Radiotherapy 3Neoadjuvant Therapy 3Maintenance 3Liquid Biopsy 3Immunotherapy, Adoptive 3Imatinib Mesylate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm, Residual × Histamine × Clear all
NCT01347996 2017-11-29

Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia

Cytovia, Inc.

Phase 4 Completed
84 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡